Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options
Authors:
- 26 April 2020
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 20 (5) , 509-516
Abstract
Introduction: Recent research has shown that IL-6 receptor (IL-6R) inhibitors like tocilizumab and satralizumab are effective in reducing the relapse rate in patients with NMOSD. Areas covered: This review article explores current concepts in NMOSD management and focuses on IL-6R as a therapeutic target. The authors delve into the biological and immunological role of IL-6 in the pathogenesis of NMOSD. Further, the authors summarize the most recent findings on the use of anti-IL-6R monoclonal antibodies, tocilizumab and satralizumab, in the treatment of NMOSD. Expert opinion: A better understanding of the role of cytokines in NMOSD may provide the neurologist with novel therapies for this disease. IL-6R appears to be a central hub to NMOSD pathogenesis and a relevant therapeutic target.Keywords
This publication has 57 references indexed in Scilit:
- The problem of choice: current biologic agents and future prospects in RANature Reviews Rheumatology, 2013
- Association of Neuromyelitis Optica With Severe and Intractable PainArchives of Neurology, 2012
- Neuromyelitis Optica: An Antibody-Mediated Disorder of the Central Nervous SystemNeurology Research International, 2012
- Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis opticaProceedings of the National Academy of Sciences, 2011
- Aquaporin-4–binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2Journal of Experimental Medicine, 2008
- Neuromyelitis optica pathogenesis and aquaporin 4Journal of Neuroinflammation, 2008
- TGF-β-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORγt functionNature, 2008
- IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cellsProceedings of the National Academy of Sciences, 2007
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosisBrain, 2005